ZAP70 interaction with 13 mRNAs as a potential immunotherapeutic target for endometrial cancer

Yuming Zhang1, Hai'ou Lu1, Yuexin Yu1

  • 1Department of Reproductive Medicine, General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, P.R. China.

Oncology Letters
|May 1, 2023
PubMed

Insights

This study identifies ζ-chain-associated protein kinase 70 (ZAP70) and related genes as potential immunotherapy targets for endometrial cancer (EC). Higher ZAP70 expression correlates with stronger immune response and better prognosis in EC patients.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Advanced, refractory endometrial cancer (EC) requires novel immunotherapeutic targets.
  • Understanding the immune microenvironment in uterine corpus endometrial carcinoma (UCEC) is crucial for treatment development.

Purpose of the Study:

  • To explore genes influencing the immune status of UCEC and identify potential immunotherapeutic targets.
  • To analyze the role of ζ-chain-associated protein kinase 70 (ZAP70) in UCEC prognosis and immune correlation.

Main Methods:

  • Weighted gene correlation network analysis and differential gene expression analysis on The Cancer Genome Atlas (TCGA) UCEC data.
  • Consensus clustering to stratify patients based on key gene expression; Gene Ontology, KEGG, and GSEA for functional enrichment.
  • Immune infiltration scoring, immune checkpoint inhibitor target expression analysis, RT-qPCR, and immunohistochemistry for ZAP70 validation.

Main Results:

  • Identified 14 key genes, including ZAP70, strongly correlated with immune status in UCEC.
  • Patients with high expression of key genes (group 2) showed enhanced immune infiltration and higher immune checkpoint expression.
  • ZAP70 was upregulated in EC tissues compared to normal tissues and associated with a protective role in EC prognosis.

Conclusions:

  • ZAP70 and its interacting genes significantly influence the immune status of EC patients.
  • ZAP70 represents a potential therapeutic target for enhancing immunotherapy efficacy in endometrial cancer.